Trial Profile

An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RO 7515629 (Primary) ; Tocilizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Roche

09 Jul 2024 Phase changed from I/II to I.
18 Apr 2024 Status changed from active, no longer recruiting to discontinued.
14 Feb 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com